Future Market Insights predicts that, in 2026, the oral obesity therapies market is being reshaped by the need to manage obesity as a chronic metabolic disease rather than a short-term weight loss intervention, as healthcare systems seek scalable, oral-first solutions to reduce long-term cardiometabolic costs.